Breast Cancer Clinical Trial

Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers

Summary

RATIONALE: Learning about thyroid dysfunction in patients with breast cancer may help plan treatment and may help patients live more comfortably.

PURPOSE: This clinical trial is studying how often thyroid dysfunction happens in women with newly diagnosed stage I, stage II, or stage III breast cancer who are planning to undergo chemotherapy compared to how often it happens in healthy volunteers.

View Full Description

Full Description

OBJECTIVES:

Primary

Compare the proportion of hypothyroidism in women with newly diagnosed stage I-IIIB breast cancer (prior to chemotherapy) vs in cancer-free, age-matched healthy volunteers.
Compare the magnitude of change in thyroid function in these patients from baseline to 24 months vs in cancer-free, age-matched healthy volunteers.

Secondary

Correlate variation in thyroid function with fatigue symptom scores.
Correlate variation in thyroid function with anthropometric measurements.

OUTLINE: This is a pilot, multicenter study.

Patients and age-matched healthy volunteers undergo blood collection at baseline and at 12 and 24 months after enrollment. They also undergo anthropometric measurements and complete the Fatigue Symptom Inventory at baseline and at 12 and 24 months after enrollment.

PROJECTED ACCRUAL: A total of 270 patients and 280 healthy volunteers will be accrued for this study.

View Eligibility Criteria

Eligibility Criteria

CASE SELECTION:

CASE INCLUSION CRITERIA:
Women between the ages of 25 and 75
Diagnosed with primary and operable Stage I - IIIB breast cancer
Scheduled to receive neoadjuvant or adjuvant Adriamycin and Cytoxan (AC) plus a taxane (taxane may be given with AC or follow AC)
No chemotherapy prior to baseline sample collection
No prior history of other cancers (except non-melanoma skin cancer)
Preoperative radiation therapy is permitted
No diagnosis of hypothyroidism or hyperthyroidism.
CASE EXCLUSION CRITERIA:
Stage IV breast cancer
Scheduled to receive neoadjuvant hormonal therapy (patients who will receive adjuvant hormonal therapy may participate)
Received adjuvant hormonal therapy or chemotherapy prior to sample collection
On chemotherapeutic regimen other than Adriamycin and Cytoxan plus a taxane.
Patients receiving monoclonal antibodies or other biologic therapy may not participate
Patients scheduled to receive Herceptin may not participate
Diagnosed with hyperthyroidism or hypothyroidism. (Women being treated for hypothyroidism are not eligible)
Women with a baseline TSH of 10 or higher will not continue on study
Women who are pregnant or lactating are not eligible. (Women of childbearing potential who are planning to become pregnant within the next 24 months should not enroll in this study)

CONTROL SELECTION:

CONTROL INCLUSION CRITERIA:
Cannot be a blood relative of the case. They can be friends, neighbors, women from social activities, local business, doctors' offices, etc.
Must live near or in the town of the case
Women between the ages of 20 and 80 (age-matched to cases +/- 5 years)
No prior history of cancer (except non-melanoma skin cancer)
Women ages 40 and older should have had a mammogram within 2 years of study entry, showing no evidence of breast cancer.
The friend control may bring their mammogram report or send a release and have records faxed to the enrolling center.
Women under the age of 40 should have had a clinical breast examination within 2 years of study entry, showing no need for diagnostic mammography. If a mammogram was required, it should show no evidence of breast cancer.
The friend control may bring their mammogram / breast exam report or send a release and have records faxed to the enrolling center.

Study is for people with:

Breast Cancer

Estimated Enrollment:

541

Study ID:

NCT00336102

Recruitment Status:

Completed

Sponsor:

University of South Florida

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 33 Locations for this study

See Locations Near You

CCOP - Western Regional, Arizona
Phoenix Arizona, 85006, United States
North Colorado Medical Center
Greeley Colorado, 80631, United States
McKee Medical Center
Loveland Colorado, 80538, United States
Cancer Centers of Central Florida, PA
Leesburg Florida, 34788, United States
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
Tampa Florida, 33612, United States
Northeast Georgia Cancer Care, LLC - Medical Oncology
Athens Georgia, 30607, United States
Medical College of Georgia Cancer Center
Augusta Georgia, 30912, United States
MBCCOP - Medical College of Georgia Cancer Center
Augusta Georgia, 30912, United States
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton Illinois, 62002, United States
Good Samaritan Regional Health Center
Mount Vernon Illinois, 62864, United States
MBCCOP - LSU Health Sciences Center
New Orleans Louisiana, 70112, United States
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
Shreveport Louisiana, 71130, United States
CCOP - Beaumont
Royal Oak Michigan, 48073, United States
William Beaumont Hospital - Royal Oak Campus
Royal Oak Michigan, 48073, United States
William Beaumont Hospital - Troy Campus
Troy Michigan, 48085, United States
MeritCare Bemidji
Bemidji Minnesota, 56601, United States
Southeast Cancer Center
Cape Girardeau Missouri, 63701, United States
Saint Francis Medical Center
Cape Girardeau Missouri, 63703, United States
David C. Pratt Cancer Center at St. John's Mercy
Saint Louis Missouri, 63141, United States
St. John's Regional Health Center
Springfield Missouri, 65804, United States
CCOP - Cancer Research for the Ozarks
Springfield Missouri, 65804, United States
Hulston Cancer Center at Cox Medical Center South
Springfield Missouri, 65807, United States
CCOP - St. Louis-Cape Girardeau
St. Louis Missouri, 63141, United States
Newark Beth Israel Medical Center
Newark New Jersey, 07112, United States
MBCCOP - Our Lady of Mercy Comprehensive Cancer Center
Bronx New York, 10466, United States
Our Lady of Mercy Medical Center Comprehensive Cancer Center
Bronx New York, 10466, United States
Mission Hospitals - Memorial Campus
Asheville North Carolina, 28801, United States
Rutherford Internal Medicine Associates, PA
Forest City North Carolina, 28043, United States
CCOP - Southeast Cancer Control Consortium
Goldsboro North Carolina, 27534, United States
Southeastern Medical Oncology Center - Goldsboro
Goldsboro North Carolina, 27534, United States
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Greensboro North Carolina, 27403, United States
Pardee Memorial Hospital
Hendersonville North Carolina, 28791, United States
Iredell Memorial Hospital
Statesville North Carolina, 28687, United States
Southeastern Medical Oncology Center - Wilson
Wilson North Carolina, 27893, United States
Forsyth Regional Cancer Center at Forsyth Medical Center
Winston-Salem North Carolina, 27103, United States
CCOP - MeritCare Hospital
Fargo North Dakota, 58122, United States
Roger Maris Cancer Center at MeritCare Hospital
Fargo North Dakota, 58122, United States
AnMed Cancer Center
Anderson South Carolina, 29621, United States
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
Spartanburg South Carolina, 29303, United States
CCOP - Scott and White Hospital
Temple Texas, 76508, United States
Scott and White Cancer Institute
Temple Texas, 76508, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

541

Study ID:

NCT00336102

Recruitment Status:

Completed

Sponsor:


University of South Florida

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider